These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

761 related articles for article (PubMed ID: 31735646)

  • 1. The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy.
    DiNatale RG; Xie W; Becerra MF; Silagy AW; Attalla K; Sanchez A; Mano R; Marcon J; Blum KA; Benfante NE; Voss MH; Motzer RJ; Coleman J; Choueiri TK; Reznik E; Russo P; Heng DYC; Hakimi AA
    Eur Urol Oncol; 2020 Feb; 3(1):47-56. PubMed ID: 31735646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy.
    Peyton CC; Abel EJ; Chipollini J; Boulware DC; Azizi M; Karam JA; Margulis V; Master VA; Matin SF; Raman JD; Sexton WJ; Wood CG; Spiess PE
    Eur Urol Focus; 2020 Jan; 6(1):104-111. PubMed ID: 30206003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.
    Bhindi B; Graham J; Wells JC; Bakouny Z; Donskov F; Fraccon A; Pasini F; Lee JL; Basappa NS; Hansen A; Kollmannsberger CK; Kanesvaran R; Yuasa T; Ernst DS; Srinivas S; Rini BI; Bowman I; Pal SK; Choueiri TK; Heng DYC
    Eur Urol; 2020 Oct; 78(4):615-623. PubMed ID: 32362493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
    Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
    Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Association Between Cytoreductive Nephrectomy and Overall Survival in Metastatic Renal Cell Carcinoma with Primary Tumor Size ≤4 cm.
    Tappero S; Barletta F; Piccinelli ML; Cano Garcia C; Incesu RB; Morra S; Scheipner L; Tian Z; Parodi S; Dell'Oglio P; Palumbo C; Briganti A; De Cobelli O; Chun FKH; Graefen M; Longo N; Ahyai S; Saad F; Shariat SF; Suardi N; Borghesi M; Terrone C; Karakiewicz PI
    Eur Urol Focus; 2023 Sep; 9(5):742-750. PubMed ID: 36906483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Bakouny Z; El Zarif T; Dudani S; Connor Wells J; Gan CL; Donskov F; Shapiro J; Davis ID; Parnis F; Ravi P; Steinharter JA; Agarwal N; Alva A; Wood L; Kapoor A; Ruiz Morales JM; Kollmannsberger C; Beuselinck B; Xie W; Heng DYC; Choueiri TK
    Eur Urol; 2023 Feb; 83(2):145-151. PubMed ID: 36272943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma.
    Lenis AT; Salmasi AH; Donin NM; Faiena I; Johnson DC; Drakaki A; Gollapudi K; Blumberg J; Belldegrun AS; Pantuck AJ; Chamie K
    Urol Oncol; 2018 Feb; 36(2):78.e21-78.e28. PubMed ID: 29128421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi-institutional retrospective study.
    Kato R; Naito S; Numakura K; Hatakeyama S; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Arai Y; Ito A; Nishiyama H; Kojima Y; Ohyama C; Habuchi T; Tsuchiya N; Obara W
    Int J Clin Oncol; 2022 Mar; 27(3):563-573. PubMed ID: 34973106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Graham J; Wells JC; Donskov F; Lee JL; Fraccon A; Pasini F; Porta C; Bowman IA; Bjarnason GA; Ernst DS; Rha SY; Beuselinck B; Hansen A; North SA; Kollmannsberger CK; Wood LA; Vaishampayan UN; Pal SK; Choueiri TK; Heng DYC
    Eur Urol Oncol; 2019 Nov; 2(6):643-648. PubMed ID: 31411994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy.
    Hahn AW; Kotecha RR; Viscuse PV; Pieretti AC; Wiele AJ; Jonasch E; Lee CH; Gao J; Zurita AJ; Shah AY; Campbell MT; Sharma P; Motzer RJ; Russo P; Wood CG; Tannir NM; Voss MH; Karam JA; Hakimi AA; Msaouel P
    Eur Urol Focus; 2023 Sep; 9(5):734-741. PubMed ID: 36863962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Takemura K; Ernst MS; Navani V; Wells JC; Bakouny Z; Donskov F; Basappa NS; Wood LA; Meza L; Pal SK; Szabados B; Powles T; Beuselinck B; McKay RR; Lee JL; Ernst DS; Kapoor A; Yuasa T; Choueiri TK; Heng DYC
    Eur Urol Oncol; 2024 Jun; 7(3):501-508. PubMed ID: 37914579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. External validation of the REMARCC model for the selection of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma: A multicenter retrospective study.
    Okita K; Hatakeyama S; Naito S; Numakura K; Kato R; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Nishiyama H; Ito A; Kojima Y; Habuchi T; Obara W; Tsuchiya N; Ohyama C
    Urol Oncol; 2021 Dec; 39(12):836.e11-836.e17. PubMed ID: 34544649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection.
    Faiena I; Salmasi A; Lenis AT; Donin NM; Johnson DC; Bachour K; Drakaki A; Belldegrun AS; Pantuck AJ; Chamie K
    Urol Oncol; 2018 Feb; 36(2):79.e19-79.e26. PubMed ID: 29103965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Primary Tumor Size on Prognosis in Patients With Metastatic Renal Cell Carcinoma Receiving Cytoreductive Nephrectomy: A Population Study of a Chinese Center and the US SEER Database.
    Jiang W; Shou J; Shi H; Wen L; Zhang H; Zheng S; Li C; Ma J
    Technol Cancer Res Treat; 2021; 20():15330338211019507. PubMed ID: 34032149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC).
    Marchioni M; Kriegmair M; Heck M; Amiel T; Porpiglia F; Ceccucci E; Campi R; Minervini A; Mari A; Van Bruwaene S; Linares E; Hevia V; Musquera M; D'Anna M; Derweesh I; Bradshaw A; Autorino R; Guruli G; Veccia A; Roussel E; Albersen M; Pavan N; Claps F; Antonelli A; Palumbo C; Klatte T; Erdem S; Mir MC;
    Eur Urol Oncol; 2021 Apr; 4(2):256-263. PubMed ID: 33384274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy.
    Fukuda H; Takagi T; Kondo T; Yoshida K; Shimizu S; Nagashima Y; Tanabe K
    Int J Clin Oncol; 2018 Jun; 23(3):539-546. PubMed ID: 29302841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival following cytoreductive nephrectomy: a comparison of existing prognostic models.
    Westerman ME; Shapiro DD; Tannir NM; Campbell MT; Matin SF; Karam JA; Wood CG
    BJU Int; 2020 Dec; 126(6):745-753. PubMed ID: 32623821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Population Study to Identify Candidates for Cytoreductive Nephrectomy in Patients with Metastatic Sarcomatoid Renal Cell Carcinoma from the Surveillance, Epidemiology, and End Results (SEER) Database.
    Ji B; Li D; Fu S; Zhang Z; Yang T; Wu Y; Zuo Y; Xu Z; Yu N
    Med Sci Monit; 2020 Jun; 26():e921297. PubMed ID: 32516796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus.
    Abel EJ; Spiess PE; Margulis V; Master VA; Mann M; Zargar-Shoshtari K; Borregales LD; Sexton WJ; Patil D; Matin SF; Wood CG; Karam JA
    J Urol; 2017 Aug; 198(2):281-288. PubMed ID: 28268170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.